Developing CAR-NK Therapies for Solid Tumors

Time: 12:00 pm
day: Day 2: Pre-Clinical & Translational


  • We are developing a “combination” CAR-NK therapy (integrating IL15 with anti-CD147 CAR-NK) that has shown a great promise in treating solid tumors in pre-clinical studies
  • We have also developed a NK / CAR-NK cell expansion technology platform with great expansion efficiency and fidelity